The reaction of [NBu 4 ] 2 [{(C 6 F 5 ) 2 Pt(μ-PPh 2 ) 2 Pt(μ-Cl)} 2 ], A, with CO in CH 2 Cl 2 gives the expected dinuclear compound [NBu 4 ][(C 6 F 5 ) 2 Pt(μ-PPh 2 ) 2 PtCl(CO)], 1, which reacts with AgClO 4 (1:1 molar ratio) in CH 2 Cl 2 to produce the tetranuclear cluster [Pt 4 (μ-PPh 2 ) 4 (C 6 F 5 ) 4 (CO) 2 ], 2 . The analogous complex [NBu 4 ] 2 [{(C 6 F 5 ) 2 Pt(μ-PPh 2 ) 2 Pd(μ-Cl)} 2 ], B, does not react with CO under similar conditions, but treatment of B with AgClO 4 (1:2 molar ratio, CH 2 Cl 2 ) renders the tetranuclear compound [Pt 2 Pd 2 (μ-PPh 2 ) 3 (C 6 F 5 ) 3 (PPh 2 C 6 F 5 )], 3, in which the PPh 2 C 6 F 5 ligand is produced through an unusual M−PPh 2 /M−C 6 F 5 reductive coupling. Complex 3 reacts with CO in CH 2 Cl 2 producing the tetranuclear complex [Pt 2 Pd 2 (μ-PPh 2 ) 2 (μ 3 -PPh(1,2-η 2 -Ph)-κ 3 P )(C 6 F 5 ) 3 (CO)(PPh 2 C 6 F 5 )], 4 . The molecular structures of complexes 2 and 4 have been established by X-ray crystallography.
No takes yet. Share an insight, caveat, or question.
Falvello et al. (1997) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: